Zim Laboratories Limited - Asset Resilience Ratio
Zim Laboratories Limited (ZIMLAB) has an Asset Resilience Ratio of 0.24% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how financially flexible is Zim Laboratories Limited to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Zim Laboratories Limited's Asset Resilience Ratio has changed over time. See how leveraged is Zim Laboratories Limited's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Zim Laboratories Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Zim Laboratories Limited.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs11.07 Million | 0.24% |
| Total Liquid Assets | Rs11.07 Million | 0.24% |
Asset Resilience Insights
- Limited Liquidity: Zim Laboratories Limited maintains only 0.24% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zim Laboratories Limited Industry Peers by Asset Resilience Ratio
Compare Zim Laboratories Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Zim Laboratories Limited (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Zim Laboratories Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 0.02% | Rs900.00K ≈ $9.73K |
Rs4.72 Billion ≈ $51.05 Million |
+0.01pp |
| 2024-03-31 | 0.01% | Rs403.00K ≈ $4.36K |
Rs4.47 Billion ≈ $48.32 Million |
0.00pp |
| 2023-03-31 | 0.01% | Rs453.00K ≈ $4.90K |
Rs3.42 Billion ≈ $36.94 Million |
-0.37pp |
| 2022-03-31 | 0.38% | Rs12.95 Million ≈ $140.00K |
Rs3.42 Billion ≈ $36.95 Million |
-4.78pp |
| 2021-03-31 | 5.16% | Rs167.65 Million ≈ $1.81 Million |
Rs3.25 Billion ≈ $35.12 Million |
+4.64pp |
| 2020-03-31 | 0.53% | Rs17.09 Million ≈ $184.85K |
Rs3.25 Billion ≈ $35.18 Million |
+2.39pp |
| 2019-03-31 | -1.86% | Rs-61.18 Million ≈ $-661.66K |
Rs3.28 Billion ≈ $35.52 Million |
-0.61pp |
| 2018-03-31 | -1.25% | Rs-37.34 Million ≈ $-403.83K |
Rs2.98 Billion ≈ $32.26 Million |
-1.25pp |
| 2017-03-31 | 0.00% | Rs1.00K ≈ $10.81 |
Rs2.59 Billion ≈ $28.02 Million |
+0.18pp |
| 2016-03-31 | -0.18% | Rs-4.56 Million ≈ $-49.36K |
Rs2.56 Billion ≈ $27.70 Million |
-- |
About Zim Laboratories Limited
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. The company offers the… Read more